BLUE
bluebird bio
BLUE
BLUE
Delisted
BLUE was delisted on the 30th of May, 2025.
81 hedge funds and large institutions have $23.7M invested in bluebird bio in 2024 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 20 increasing their positions, 31 reducing their positions, and 72 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more ownership
Funds ownership: →
less capital invested
Capital invested by funds: $ → $
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
41% less funds holding
Funds holding: 138 → 81 (-57)
76% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 72
Holders
81
Holding in Top 10
1
Calls
$40.7M
Puts
$4.89M
Top Buyers
| 1 | +$886K | |
| 2 | +$714K | |
| 3 | +$662K | |
| 4 |
Jane Street
New York
|
+$239K |
| 5 |
Goldman Sachs
New York
|
+$190K |
Top Sellers
| 1 | -$674K | |
| 2 | -$668K | |
| 3 | -$555K | |
| 4 |
Renaissance Technologies
New York
|
-$550K |
| 5 |
Millennium Management
New York
|
-$531K |